Agilent highlighted how lab automation and instrumentation are being used to scale antibody-drug conjugate (ADC) characterization workflows. The story focuses on practical acceleration and reproducibility for targeted biologic development, where variability in analytical methods can slow candidate selection. By improving throughput and reducing measurement-to-measurement inconsistency, automation can help teams evaluate conjugation chemistry, stability, and product quality attributes earlier in development. This can translate into faster iteration cycles across discovery, preclinical, and development stages. For biotech process development and CMC stakeholders, the core impact is less about clinical outcomes and more about time-to-data for ADC programs—especially as ADC pipelines expand and companies face tighter schedules for IND-enabling work.